Prescription drug prices in the United States have recorded their steepest annual decline in more than six decades, giving the Trump administration a significant economic statistic to tout while analysts debate exactly what caused the drop.
According to the Bureau of Labor Statistics’ latest Consumer Price Index report, prescription drug prices fell 0.8 percent in July and were 3.1 percent lower than a year earlier.
That represents the largest year-over-year decline in more than 60 years.
The White House credited President Donald Trump’s policies, saying the numbers demonstrate that the administration is “delivering real relief to American families and putting patients first.”
Health policy analysts, however, say several forces are operating simultaneously.
“As with most industries, a range of factors impact drug prices,” Institute for Legislative Analysis President Fred McGrath told the Daily Caller News Foundation.
McGrath pointed particularly to competition from generic drugs and biosimilars.
“Arguably, the largest driver is generic competition,” he said. “Over the last year, several brand drugs representing tens of billions in annual revenue have seen significant price drops from biosimilar competition.”
Government policy may also be contributing.
In February, Trump signed the Consolidated Appropriations Act into law. The legislation included reforms aimed at pharmacy benefit managers, or PBMs, the intermediaries that negotiate prescription drug prices and benefits among drug manufacturers, insurers and pharmacies.
McGrath argued those changes have likely had a substantial effect.
“From a policy perspective, the Pharmacy Benefit Manager (PBM) reform package President Trump signed earlier this year has likely had the biggest impact,” he said.
Sen. Bill Cassidy of Louisiana, who backed the reforms, put the issue more directly when Trump signed the legislation.
PBM programs “should be about lowering the cost for patients, not about increasing profit for shareholders,” Cassidy said.
Geoffrey Joyce, director of health policy at the University of Southern California’s Schaeffer Center for Health Policy and Economics, also identified PBM scrutiny as a possible factor.
“Spotlight on PBMs and proposed PBM reforms has led to a reduction in business as normal in the [prescription drug] supply chain,” Joyce told the DCNF.
He also pointed to “increased transparency into the inefficiencies of the Rx drug market.”
The administration has pursued other changes.
Trump signed a May 2025 executive order seeking to bring American prescription costs in line with “most-favored-nation” pricing, an approach intended to prevent Americans from paying substantially more for certain medications than patients in comparable countries.
The administration has also expanded TrumpRx, its direct-to-consumer prescription platform. In May, the White House announced that more than 600 generic medications were being added.
Brownstone Institute President Jeffrey Tucker attributed at least some of the decline to greater retail competition.
“In my own view, this is due to growing competition in the retail sector, partly due to TrumpRx, but there are many other entries to this as well,” Tucker said. “It’s increased price competition as new distribution methods replace more cartelized systems of the past.”
But the numbers do not mean every American medication suddenly became cheaper.
NPR reported in January that 16 pharmaceutical companies that had reached agreements with the Trump administration nevertheless raised some prices for 2026.
McGrath also cautioned against assuming that the current rate of decline will continue.
“Large decreases or increases are unlikely this year,” he said.
He expressed particular skepticism about attributing the recent decline primarily to most-favored-nation pricing, noting that MFN drugs account for fewer than 10 percent of the 841 medications listed on TrumpRx.
House Speaker Mike Johnson nevertheless seized on the latest numbers.
“Prescription drug prices are now at their LOWEST LEVELS in more than 60 years — because of @POTUS and Republicans working to bring down costs for all Americans,” Johnson wrote Sunday on X.
Prescription drug prices are now at their LOWEST LEVELS in more than 60 years — because of @POTUS and Republicans working to bring down costs for all Americans.
This is what delivering real, positive results for the American people looks like. https://t.co/iX30GJPDg8
— Speaker Mike Johnson (@SpeakerJohnson) August 16, 2026
